B of A Securities Maintains Neutral on C4 Therapeutics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Chi Fong maintains a Neutral rating on C4 Therapeutics (NASDAQ:CCCC) and lowers the price target from $5 to $2.
October 09, 2023 | 11:47 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
B of A Securities has maintained a Neutral rating on C4 Therapeutics and lowered the price target from $5 to $2.
The lowering of the price target by B of A Securities from $5 to $2 indicates a negative outlook for C4 Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100